350 FIFTH AVENUE, NEW YORK, NY
Rocket Pharmaceuticals Adopts Severance and Change in Control Program
Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
VP of Finance John Militello Resigns; Joseph Manhede Appointed Principal Acco...
Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Stockholders Elect Seven Directors at Rocket Pharmaceuticals Annual Meeting
Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Announces $180 Million Sale of Priority Review Voucher
Q2
FY 2024
Q3
Q1
Registration Statement for Securities to be Offered to Employees
SC TO-I
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement